Tenaya to Reveal One-Year TN-401 ARVC Data and Q2 MyPEAK-1 Updates
TNYA•Tenaya Therapeutics reported Q1 2026 results and announced it will present one-year Cohort 1 plus initial Cohort 2 RIDGE-1 TN-401 data at ASGCT May 15; interim MyPEAK-1 TN-201 data from 3E13 and 6E13 vg/kg cohorts due in Q2 2026. It also advanced TN-301 DMD data and began Alnylam collaboration.
1. Q1 2026 Results and Pipeline Highlights
Tenaya reported first quarter 2026 financial results for the period ended March 31 and highlighted a catalyst-rich pipeline with multiple clinical data readouts and partnerships planned for 2026.
2. TN-201 MYBPC3-Associated HCM Updates
In the MyPEAK-1 Phase 1b/2 trial for MYBPC3-associated HCM, investigators optimized immunosuppressive dosing and resumed enrollment after FDA-aligned amendments; interim safety and dosing data for 3E13 and 6E13 vg/kg cohorts will be presented in Q2.
3. TN-401 PKP2-Associated ARVC Data Plans
In the RIDGE-1 Phase 1b/2 trial for PKP2-associated ARVC, a DSMB endorsed continued enrollment after reviewing safety data from six patients, and one-year Cohort 1 plus initial Cohort 2 results will be presented at ASGCT on May 15, followed by a webcast.
4. TN-301 Preclinical Success and Alnylam Collaboration
TN-301, a selective HDAC6 inhibitor, achieved wild-type grip strength in DMD models at 3 mg/kg, improved cardiomyocyte function, and earned Rare Pediatric and Orphan Drug designations, while a collaboration with Alnylam will target genetic drivers of cardiovascular disease.
